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Abstract
Background: The safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine
(Sub/MF59™; FLUAD®, Novartis Vaccines) was evaluated among elderly Chinese subjects (≥ 60
years of age). After a preliminary Phase I, open-label study (n = 25) to assess safety 1–14 days post-
vaccination, a comparative observer-blind, randomised, controlled clinical trial (n = 600) was
performed to assess safety and immunogenicity versus a non-adjuvanted subunit influenza vaccine
(Subunit; Agrippal®, Novartis Vaccines). Subjects were randomised (2:1) to receive Sub/MF59™ or
Subunit.
Results:  Both vaccines were well tolerated, with no vaccine-related serious adverse events
reported during the Phase I trial. During the observer-blind study, local and systemic reactions
were generally similar for both vaccines 1–22 days post-vaccination; however, injection-site
induration was more frequent among the Subunit group (P < 0.05), and mild pain at the injection
site and fever were more frequent among Sub/MF59™ recipients (P ≤ 0.005). Both vaccines
induced a significant (P < 0.001) increase in geometric mean titres (GMTs) for the three strains
tested, versus baseline; GMTs against A/H1N1, A/H3N2 and B were significantly higher in the Sub/
MF59™ group (P = 0.034, P < 0.001 and P = 0.005, respectively). GMT ratios against A/H1N1, A/
H3N2 and B were also significantly higher in the Sub/MF59™ group (P = 0.038, P < 0.001 and P =
0.006, respectively). Similarly, the percentage of subjects achieving seroprotection or
seroconversion on Day 22 was greater for Sub/MF59™ recipients, reaching significance for A/
H3N2 (P < 0.001).
Conclusion: MF59™-adjuvanted subunit influenza vaccine is well tolerated by elderly Chinese
subjects and induces a higher level of immunogenicity than a non-adjuvanted subunit influenza
vaccine in this population that is at high risk of influenza-related complications.
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Background
Influenza infection represents a considerable global bur-
den, affecting 5–15% of the adult population during
annual influenza epidemics [1]. Each year, 3–5 million
cases of severe illness and 250,000–500,000 deaths are
thought to result from these epidemics worldwide [1,2].
South-east Asia is considered to be the global influenza
epicentre, with several pandemic and epidemic strains
known to have originated from China and Hong Kong
since 1957 [3-5]. Furthermore, China is generally
acknowledged as an area with a high influenza attack rate,
due to the high population density and year-round circu-
lation of the virus in tropical regions [6,7]. In China,
pneumonia and influenza combined ranks fourth in the
leading causes of death in adults (≥ 40 years of age) [8].
Due to their weakened immune response, the elderly are
at increased risk of influenza and its related complications
[9]. In China, the annual mortality rate for pneumonia
and influenza has been reported to rise to 227.4/100,000
persons in the elderly (≥ 65 years of age), representing a 5-
fold increase from the age-standardised annual mortality
rate of 43.9/100,000 persons [8]. Furthermore, during
1999, the reported number of influenza-associated deaths
in Hong Kong from cardiorespiratory disease, pneumonia
and influenza, chronic obstructive pulmonary disease and
ischaemic heart disease was higher in the elderly (1697
deaths), compared with adults (205 deaths; 40–64 years
of age) [10]. Peaks in influenza circulation have been
shown to coincide with increased mortality from these
conditions, with the elderly accounting for approximately
70–90% of the associated deaths [10]. In addition to an
increased number of deaths [10,11], the hospitalisation
rate for pneumonia and influenza is also high in the eld-
erly [12].
Influenza vaccine effectiveness has been studied exten-
sively, mainly in temperate regions. Conventional influ-
enza vaccines confer protection against laboratory-
confirmed influenza in 70–90% of young adults (18–64
years of age) [13,14]; however, these vaccines are less
effective (17–53%) in the elderly, due in part to the eld-
erly's waning immunity [15]. When evaluating vaccine
response, however, it is important to also consider racial
background. For example, among a racially diverse,
healthy elderly population in the USA, a reduced response
to influenza vaccine was observed among elderly African
Americans, compared with elderly Caucasian and Latinos
[16]. Furthermore, racial differences in relation to vaccina-
tion have been observed in Taiwan among Han Chinese
children compared with Aboriginal children; higher titres
against hepatitis B vaccination were reported for Han Chi-
nese children [17].
In Hong Kong, Taiwan and China, vaccination has been
shown to offer protection against influenza [18-20]. Influ-
enza vaccination prevented approximately 69% of influ-
enza-related hospitalisation admissions in Hong Kong
during the 2003–2004 winter season [19] and was
strongly associated with a reduction in pneumonia, heart
disease, stroke, diabetes mellitus and renal disease in Tai-
wan in 2001 [20]. Vaccine effectiveness, however, has also
been reported to be lower in elderly Chinese people than
in adult Chinese people (68.6% versus 74%, respectively)
[18]. Despite the availability of an effective vaccine, cover-
age rates are low in China; for example, the general vacci-
nation rate among the urban population of Beijing is only
10.5%, falling to 7.9% for those ≥ 60 years of age [21].
Thus, because currently available vaccines do not offer
optimal protection in the elderly [14,15] and vaccine cov-
erage rates are low [21], elderly Chinese people are at
increased risk of influenza and its related complications.
As China has the world's largest population of elderly
people (>80 million) [22], influenza represents a consid-
erable health and economic burden.
To meet the global challenge presented by waning immu-
nity in the elderly, vaccines that offer the elderly enhanced
immunogenicity and increased clinical protection are
required. Addition of the adjuvant MF59™ [23] to subunit
influenza vaccine (MF59™-adjuvanted subunit influenza
vaccine; FLUAD®, Novartis Vaccines) has been shown to
enhance the immune response and offer increased clinical
protection in elderly subjects, compared with non-adju-
vanted subunit influenza vaccine [24-26]. Furthermore,
enhanced immunogenicity is observed in elderly subjects
with underlying chronic conditions, who are at especially
high risk of influenza and its complications [27]. Vaccina-
tion of elderly subjects with the MF59™-adjuvanted subu-
nit influenza vaccine also confers protection against a
broader range of influenza virus strains than non-adju-
vanted subunit influenza vaccine [28,29] and has been
associated with a reduced risk of hospitalisation for pneu-
monia and cerebrovascular disease in non-institutional-
ised elderly subjects [30,31].
In China, the registration of FLUAD® for use in elderly
people is currently under consideration. For this reason, a
randomised comparative trial was performed in a large
cohort of elderly Chinese people to assess the safety and
immunogenicity of FLUAD®  against a non-adjuvanted
subunit influenza vaccine.
Results
All subjects (n = 25) enrolled in the Phase I open-label
trial completed the safety evaluation. One subject was
excluded from the analysis due to administration of Sub-
unit vaccine, rather than Sub/MF59™. For the Phase II/III
trial, the baseline characteristics of the study populationImmunity & Ageing 2008, 5:2 http://www.immunityageing.com/content/5/1/2
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were similar for the Sub/MF59™ and Subunit vaccine
groups, with an equal match for gender, age and availabil-
ity of current and past medical history. A total of 600 sub-
jects were recruited in the subsequent Phase II/III trial and
randomised to receive Sub/MF59™ (n = 400) or Subunit
(n = 200) vaccine. Safety evaluation was completed for
589 subjects and serological analysis was performed for
554 subjects (Figure 1). The major reasons for patient
withdrawal were refusal to continue the study (25 and 10
subjects receiving Sub/MF59™ and Subunit, respectively),
a change in residence or hospital/being unable to receive
follow-up as too busy (4 patients, 2 in each vaccine group)
or other drop-out (6 and 1 subjects receiving Sub/MF59™
and Subunit, respectively). No subjects were withdrawn
from the study because of an AE due to the study vaccines.
Safety
Both vaccines were well tolerated by elderly subjects dur-
ing the clinical trials. No vaccine-related serious adverse
events (SAEs) were reported for Sub/MF59™ during the
Phase I trial, which was a pre-requisite for continuation
with the Phase II/III trial.
In the Phase II/III trial, the overall incidence of systemic
reactions and AEs was generally similar between the Sub/
MF59™ and Subunit groups; however, the incidence of
local reactions was significantly (P = 0.012) higher in the
Sub/MF59™ group compared with the Subunit group
(24.0% versus 15.2%, respectively) (Table 1). Induration
at the injection site was significantly (P < 0.05) more fre-
quent in the Subunit group compared with the Sub/
MF59™ group (2.5% versus 0.5%, respectively) (Table 2).
Pain at the injection site and fever (axillary temperature
>38°C) were significantly (P ≤ 0.005) more frequent in
the Sub/MF59™ group compared with the Subunit group
(10.2% versus 3.0% and 15.9% versus 7.6%, respectively)
(Table 2). Local and systemic reactions were generally
mild or moderate and transient. In particular, fever was
mainly classed as mild or moderate in the Sub/MF59™
and Subunit groups and pain was classified as mild. No
vaccine-related SAEs were reported during this large study
for the Subunit group; however, a vaccine-related SAE
(high fever) was reported for one subject (0.3%) in the
Sub/MF59™ group (Table 1).
Immunogenicity
Pre-vaccination GMTs were similar for both vaccine
groups against all three influenza strains tested. Baseline
seroprotection rates were also similar between vaccine
groups, with >97% of subjects in each vaccine cohort sero-
protected against A/H1N1 (Sub/MF59™, 98.4%; Subunit,
97.3%), >18% against A/H3N2 (Sub/MF59™, 21.5%;
Subunit, 18.7%) and >2% against B (Sub/MF59™, 2.2%;
Subunit, 2.1%) prior to vaccination (Table 3).
At 3 weeks post-vaccination, significantly (P < 0.001)
higher GMTs were reported for both vaccine groups versus
baseline (data not shown); however, in the Sub/MF59™
group, post-vaccination GMTs against all three strains
were significantly higher compared with the Subunit
group (A/H1N1, 1439.01 versus 1197.39, respectively, P
= 0.034; A/H3N2, 274.61 versus 110.85, respectively, P <
0.001; B, 16.59 versus 11.95, respectively, P = 0.005). Fur-
thermore, GMT ratios (Day 22:Day 1) against the A/
H1N1, A/H3N2 and B strains were significantly (P =
0.038, P < 0.001, P = 0.006, respectively) greater in the
Sub/MF59™ group compared with the Subunit group (Fig-
ure 2). Following analysis of the data, including only
those subjects who did not have seroprotective titres prior
to vaccination, the same trend was found: higher post-vac-
cination GMTs were reported in the Sub/MF59™ group
compared with the Subunit group for the A/H3N2 and B
strains (P < 0.001 and P = 0.008, respectively), but not for
A/H1N1 (Figure 3).
Post-vaccination, the percentage of subjects seroprotected
against the A/H3N2 strain was significantly (P < 0.001)
greater after vaccination with Sub/MF59™ compared with
Subunit vaccination (Table 3). Although the seroprotec-
tion rate for all subjects against the A/H1N1 and B strains
was higher in the Sub/MF59™ group, no significant differ-
ence was found between vaccine groups. In addition, a
significantly (P < 0.001) greater number of previously
Subject participation in the Phase II/III trial Figure 1
Subject participation in the Phase II/III trial.Immunity & Ageing 2008, 5:2 http://www.immunityageing.com/content/5/1/2
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unprotected elderly subjects in the Sub/MF59™ vaccine
group demonstrated seroconversion against the A/H3N2
strain, compared with the Subunit group (85.1 versus
66.2%, respectively) (Table 4).
Discussion
This study has demonstrated that MF59™-adjuvanted sub-
unit influenza vaccine is as well tolerated as non-adjuvan-
ted subunit influenza vaccine in elderly Chinese subjects.
Although the number and incidence of some of the solic-
ited local reactions in the Sub/MF59™ vaccine group was
greater than in the Subunit group, they were generally
mild or moderate and of short duration, and no subjects
withdrew from the study due to safety concerns. Further-
more, the incidence of injection-site pain reported here
was lower than has been reported in other studies [25,27].
Although the incidence of fever was higher than has been
reported previously with MF59™-adjuvanted influenza
vaccination [25,27], the increased incidence was evident
for both vaccines used in this study, rather than for the
Sub/MF59™ vaccine only. The increase does not appear to
be due to race, as in a previous study in elderly Chinese
subjects [19] the incidence of fever was 0% following vac-
cination with non-adjuvanted influenza vaccine. These
findings are in agreement with the published results of
clinical trials conducted in elderly Caucasian populations
in Europe [25]. These trials supported registration of the
vaccine in Europe, and concluded that the addition of
MF59™ to subunit influenza vaccines does not cause clin-
ically important changes in the safety profile of the influ-
enza vaccine. To date, more than 30 million doses of the
MF59™-adjuvanted subunit influenza vaccine have been
sold, and it has demonstrated a good safety profile [32].
Evaluation of post-marketing pharmacovigilance case
reports (n = 385; September 1997 to April 2006) con-
firmed that vaccination with the MF59™-adjuvanted sub-
Table 1: Incidence of adverse events (AEs), adverse reactions and serious AEs (SAEs) for the two vaccine groups
Incidence, %(n) P-value
Sub/MF59™ (n = 391) Subunit (n = 198)
Local reactions 24.0(94) 15.2(30) 0.012
Systemic reactions 10.7(42) 9.6(19) 0.666
AEs 6.1(24) 6.6(13) 0.840
SAEs 1.0(4) 0.5(1) 0.668
Vaccine-related AEs (definitely, probably or possibly related to the vaccine) 3.8(15) 5.1(10) 0.490
Vaccine-related SAEs (definitely, probably or possibly related to the 
vaccine)
0.3(1) 0.0(0) 1.000
Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine
Table 2: Incidence of local and systemic reactions reported for the two vaccine groups
Sub/MF59™ %(n) Subunit %(n)
Local reaction Rash 0.0(0) 0.5(1)
Erythema 1.5(6) 1.5(3)
Induration 0.5(2) 2.5(5)*
Swelling 2.8(11) 1.0(2)
Pain 10.2(40)** 3.0(6)
Pruritus 1.3(5) 3.0(6)
Systemic reaction Headache 3.6(14) 2.5(5)
Fever 15.9(62)** 7.6(15)
Tiredness 3.3(13) 1.0(2)
Diarrhoea 0.8(3) 2.0(4)
Vomiting 1.0(4) 1.0(2)
Myalgia 1.8(7) 0.5(1)
Cough 2.0(8) 2.0(4)
Angina 1.5(6) 1.0(2)
Watery nasal discharge 1.0(4) 1.0(2)
Skin disease (e.g. eczema) 0.0(0) 1.0(2)
Irritability 0.0(0) 0.5(1)
*P < 0.05 versus the Sub/MF59™ vaccine group; **P ≤ 0.005 versus the Subunit vaccine group
Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccineImmunity & Ageing 2008, 5:2 http://www.immunityageing.com/content/5/1/2
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unit influenza vaccine was associated with a very low
frequency of adverse reactions [33].
Evaluation of the primary (pre- and post-vaccination
GMTs and GMT ratio) and secondary (proportion of sub-
jects with protective antibody titres [≥ 40] and those dem-
onstrating seroconversion post-vaccination)
immunogenicity parameters showed that both the Sub/
MF59™ and Subunit vaccines were able to induce an
immune response in elderly Chinese subjects. Signifi-
cantly (P < 0.05) higher antibody titres were induced by
the Sub/MF59™ vaccine compared with the Subunit vac-
cine. Furthermore, as for the safety profile, the immuno-
genicity results agree with the results of trials conducted in
Europe [24,25,27]. For all three influenza strains tested,
both the MF59™-adjuvanted and the non-adjuvanted vac-
cine met at least one criterion of the European Committee
for Medicinal Products for Human Use (CHMP) criteria
for the immunogenicity evaluation of seasonal influenza
vaccines, as required for vaccine licensure [34]. For both
vaccines, the trend was for higher immunogenicity for the
influenza A strains, compared to the B strain. It is of note
that very high pre-vaccination titres were recorded in this
study, especially for A/H1N1. This could be explained in
part by the A/H1N1 vaccine strain (A/New Caledonia/20/
99-like H1N1) being included in the vaccine formulation
for several influenza seasons previous to the 2005–2006
season. Furthermore, from an epidemiological stand-
point, influenza A strains are often the most dominant
and the most relevant strains among adults and the eld-
erly, with A/H1N1 having been the predominant circulat-
ing strain in the Guangxi region of China during the time
before the trial was conducted.
It is well documented that levels of HI antibody titres cor-
relate with seroprotection against influenza [35], thus it is
expected that increased immunogenicity should lead to
increased clinical protection from influenza. This
approach has been widely used across the clinical trial
programme for the MF59™-adjuvanted vaccine [25]. Dur-
ing field studies in Europe, MF59™-adjuvanted vaccine
has been shown to offer greater clinical protection against
influenza-like illness compared with non-adjuvanted vac-
cine [26]. Therefore, it is anticipated that MF59™-adjuvan-
ted vaccine may also offer greater clinical protection in
elderly Chinese subjects.
Results from trials using an MF59™-adjuvanted subunit
influenza vaccine suggest that adjuvanted vaccination
induces a greater immune response in elderly (≥ 60 years
of age) Chinese subjects, and demonstrates a good tolera-
bility profile, compared with a non-adjuvanted subunit
influenza vaccine.
Conclusion
In conclusion, the study results strengthen support for the
use of the MF59™-adjuvanted subunit influenza vaccine
(FLUAD®) among the elderly population in China.
Table 3: Pre- and post-vaccination seroprotection rate (percentage of subjects with haemagglutination inhibition titre ≥ 1:40)
Viral strain Vaccination status Sub/MF59™, % (n = 367) Subunit, % (n = 187)
A/H1N1 Pre-vaccination 98.4 97.3
Post-vaccination 99.7 99.5
A/H3N2 Pre-vaccination 21.5 18.7
Post-vaccination 88.0* 72.2
B Pre-vaccination 2.2 2.1
Post-vaccination 35.7 28.3
*P < 0.001 versus the Subunit group
Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine
Geometric mean titre ratios (Day22:Day1) in all subjects in  the Phase II/III trial Figure 2
Geometric mean titre ratios (Day22:Day1) in all sub-
jects in the Phase II/III trial.Immunity & Ageing 2008, 5:2 http://www.immunityageing.com/content/5/1/2
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Methods
Study design
A preliminary Phase I, open-label study was conducted in
February-March 2006 to assess the safety of an MF59™-
adjuvanted subunit influenza vaccine (Sub/MF59™;
FLUAD®, Novartis Vaccines) in elderly Chinese subjects.
The study recruited 25 Chinese subjects (≥ 60 years of
age); of these, 24 subjects were administered Sub/MF59™
in follow-up sequence.
Following this safety trial, a Phase II/III randomised,
observer-blind, controlled study was conducted to assess
the safety and immunogenicity of Sub/MF59™ in a large
cohort of elderly (≥ 60 years of age) Chinese subjects. Sub-
jects were randomised (2:1) to receive either Sub/MF59™
(n = 400) or a non-adjuvanted subunit influenza vaccine
(Subunit; Agrippal®, Novartis Vaccines; n = 200). Both
vaccines included the strains recommended for the
2005–2006 Northern hemisphere influenza season. Ran-
domisation was achieved using the PEMS V2.1 statistical
software (Statistics Teaching and Research Division, West
China University of Medical Sciences; released January
1996). A 0.5 ml dose was administered intramuscularly in
the deltoid region of the non-dominant arm.
Study population
Inclusion criteria
Subjects invited to participate in the trial were those ≥ 60
years of age, who were healthy and willing/able to provide
written informed consent prior to study entry.
Exclusion criteria
Subjects with underlying disease chronic, such as
tumours, autoimmune diseases, progressive artheroscle-
rosis or complicated diabetes mellitus, chronic obstruc-
tive pulmonary disorder requiring oxygen therapy, acute
Table 4: Seroconversion rates (percentage of subjects with 
seroconversiona or a significant increase in HI titresb in subjects 
without pre-vaccination immunoprotection)
Seroconversion rates, %
Viral strain Sub/MF59™ Subunit
A/H1N1c 83.3 80.0
A/H3N2d 85.1* 66.2
Be 33.4 25.8
aSeroconversion is defined as negative pre-vaccination serum (i.e. 
haemagglutinin inhibition [HI] titre <1:10) and post-vaccination HI 
titre ≥ 1:40; bSignificant increase is defined as ≥ 4-fold increase from 
non-negative (≥ 1:10) pre-vaccination HI titre; cNumber of subjects: 
Sub/MF59™, 6; Subunit, 5; dNumber of subjects: Sub/MF59™, 288; 
Subunit, 152; eNumber of subjects: Sub/MF59™, 359; Subunit, 183
*P < 0.001 versus the Subunit group
Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, 
non-adjuvanted subunit influenza vaccine
Pre-vaccination (Day 1) and post-vaccination (Day 22) geo- metric mean titre against a) A/H1N1, b) A/H3N2 and c) B  viral strains in subjects without pre-vaccination immunopro- tection Figure 3
Pre-vaccination (Day 1) and post-vaccination (Day 
22) geometric mean titre against a) A/H1N1, b) A/
H3N2 and c) B viral strains in subjects without pre-
vaccination immunoprotection.Immunity & Ageing 2008, 5:2 http://www.immunityageing.com/content/5/1/2
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or progressive liver or renal disease, or congestive heart
failure; subjects with a known allergy to any vaccine com-
ponents; subjects with laboratory-confirmed influenza or
vaccinated against influenza within 6 months prior to
enrolment; subjects who had received any other vaccine
or investigational agent within 4 weeks prior to enrol-
ment; subjects with current infectious disease, including
those taking systemic antibiotics or antivirals.
Both the pivotal safety study and the subsequent trial were
performed according to the ethical guidelines of the 1975
Declaration of Helsinki, Good Clinical Practice, and local
laws. Before the trials started, the study protocol and
informed consent form were approved by local ethics
committees; all subjects signed an Informed Consent
Form.
Objectives
Safety
Local and systemic reactions, including all adverse events
(AEs), were monitored and recorded 14 days post-vacci-
nation for the Phase I trial and 22 days post-vaccination
for the Phase II/III trial, controlled study.
Immunogenicity
For the Phase II/III trial, blood samples were taken from
all subjects pre-vaccination (Day 1) and post-vaccination
(Day 22). Haemagglutinin inhibition (HI) antibody titres
were measured in all samples. Primary parameters: Geo-
metric mean titres (GMTs) against A/New Caledonia/20/
99-like (A/H1N1), A/California/7/2004-like (A/H3N2)
and B/Shanghai/361/2002-like influenza strains were
measured for each vaccine pre- and post-vaccination (Day
1 and Day 22). The geometric mean titre ratio (GMR) of
post-vaccination titres versus pre-vaccination titres was
also reported. Secondary parameters: For each influenza
strain, the number of subjects with seroprotective HI anti-
body titres (≥ 1:40) was also evaluated pre-vaccination
and post-vaccination (Day 1 and Day 22), and the
number of subjects achieving seroconversion (defined as
≥ 4-fold increase in HI titre from non-negative pre-vacci-
nation titre [≥ 1:10] or a rise from <1:10 to a post-vaccina-
tion HI titre ≥ 1:40) post-vaccination (Day 22) was
calculated.
Statistical methods, analysis and objectives
Data were analysed using the SAS V8.2 software. Statistical
significance between vaccine groups for data describing
the population's baseline characteristics was calculated
using the Student's t-test and the chi-square test, or
Fisher's exact test where necessary. Analysis of covariance
was performed to calculate the confidence intervals for
GMTs at Day 22, with GMT at Day 1 as covariate. Paired t-
tests were performed to assess the difference between pre-
and post-vaccination GMTs within each vaccine group. A
P-value of <0.05 was considered to indicate statistical sig-
nificance.
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